Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Publication at Central Library of Charles University |
Treatment with fumarate reduced number of new active lesions in magnetic resonance and number of relapses. Treatment was safe and generally well tolerated.
The results entitle to continue in long-term phase III study in large patient population.